An interventional study of Usual Care group and Technological group in Type 2 Diabetes Mellitus (T2DM), Continuous Glucose Monitoring and CGM, sponsored by Instituto de Investigacion Sanitaria La Fe. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 332nd largest by planned enrollment of the 383 interventional ones that give a count, is one of 16 that started in 2024, is one of 77 with no phase, reaches primary completion later than 16 of the 54 other live ones, and was the 394th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Spain, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 49 · Phase 3 209 · Phase 4 51
First in 2000; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 484 across the 383 interventional studies, 842 across the 46 observational. Of the 346 that completed or were terminated, 197 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
304 of 429 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigacion Sanitaria La Fe is the lead sponsor of 58 studies on the registry; 12 are open to participants now.
Instituto de Investigacion Sanitaria La Fe has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus, Type 2 with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07269015Hospital Mutua de TerrassaCGM Accuracy in Pregnancy Study | 2026-12 |
| NCT06871059University of the Balearic IslandsEffectiveness, Implementation and Spillover Effects of a Culturally Adapted DPP in Spanish Primary Care Centers | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study explores whether adding technological tools during hospital discharge can help people with type 2 diabetes who are starting insulin therapy achieve better treatment adherence and blood glucose control once they return home. The discharge transition period includes both the final days of hospitalization and the first weeks to months after returning home.
When people with type 2 diabetes are hospitalized, they sometimes need to begin insulin therapy. After discharge, managing insulin properly is essential to avoid high or low blood sugar levels. However, many patients forget or delay insulin doses, which can lead to poor control of their diabetes.
This study will compare two groups of patients. All participants will be adults with type 2 diabetes, between 18 and 70 years old, who are newly starting insulin during their hospital stay.
Group 1 ("technological group") will use a continuous glucose monitor (CGM) and a smart insulin pen cap called Insulclock. These tools show real-time blood glucose data and record when and how much insulin is injected. Patients and doctors can use this information to better adjust treatment. Insulclock also includes alarms to remind patients of their doses.
Group 2 ("control group") will use the same devices, but they will not see the data in real time. Instead, they will manage their insulin based on standard finger-prick blood sugar checks four times a day, as typically done in standard care.
Both groups will be followed for 12 weeks after hospital discharge. Medical check-ins will occur in weeks 1, 2, 4, 8, and 12. Blood tests and treatment adjustments will be performed as needed.
The main goals are:
To measure if the use of technology helps patients stick to their insulin schedule (fewer missed or mistimed injections).
To see if it leads to better blood glucose control (e.g., more time within the recommended range, fewer episodes of low or high glucose).
To evaluate patient satisfaction with this technology and check if the number of unplanned hospital readmissions decreases.
The study will take place at Hospital Universitari i Politècnic La Fe in Valencia, Spain. Around 80 patients will participate.
This study is important because real-world data about the use of CGM and smart insulin devices during the hospital-to-home transition are limited. It may help improve diabetes care for people starting insulin after hospitalization.
The transition from hospital to home is a clinically vulnerable phase for patients with type 2 diabetes mellitus (T2DM), particularly for those who are newly initiated on insulin therapy during hospitalization. This period is characterized by increased therapeutic complexity, limited patient confidence with insulin use, and heightened risk of poor glycemic outcomes. Suboptimal adherence to insulin regimens-including missed or delayed doses-is common and has been associated with adverse clinical events, reduced quality of life, and higher healthcare utilization, including unplanned readmissions.
While continuous glucose monitoring (CGM) systems and smart insulin pen caps have individually shown promise in improving glycemic control and treatment adherence, there is a lack of robust data regarding their effectiveness when introduced in the peri-discharge period. Importantly, the transition from inpatient to outpatient care has been highlighted as a critical moment to implement structured, technology-supported interventions aimed at improving self-management and continuity of care.
This study investigates whether the combination of CGM and Insulclock® technology, initiated during hospitalization and continued after discharge, improves glycemic control and adherence in insulin-treated T2DM patients. Unlike prior studies, this trial evaluates these devices not only as monitoring tools but also as real-time decision-making supports during a period of high clinical risk.
In addition to assessing standard glycemic metrics - including time in range (TIR), time below and above range (TBR, TAR), coefficient of variation, and HbA1c - the study will measure patient-reported treatment satisfaction and unplanned hospital readmissions within 30 days. The outcomes of this research may inform future protocols for diabetes discharge planning and support the integration of connected technologies into standard care pathways for insulin initiation in hospitalized patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
From discharge, use of a blind continuous glucose sensor and a smart insulin pen cap. Insulin therapy decision-making based on capillary blood glucose.
Device: Usual Care group
From discharge, a continuous glucose sensor and smart insulin pen cap are used, and the subject is able to see its parameters. Insulin therapy decision-making is based on the continuous glucose sensor and smart cap parameters.
Device: Technological group
Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.
Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.
Therapeutic adherence
Assessment of therapeutic adherence based on the number of injustified insulin administration omissions per week. Measured by Number of missed basal and bolus insulin doses within any 14-day period during follow-up. Method of Assessment: Data will be collected through the digital insulin pen smart cap system (Insulclock®), which automatically records each insulin administration and detects missed doses.
Time frame: From baseline (hospital discharge) to 12 weeks post-discharge
Time in Range
Percentage of time that interstitial glucose values remain within the target range of 70 to 180 mg/dL, as measured by continuous glucose monitoring (CGM). This metric reflects the effectiveness of glycemic control in patients with type 2 diabetes. TIR is widely recognized as a clinically meaningful outcome in diabetes technology studies. Unit of Measurement: Percentage (%) of time in target range Method of Assessment: data will be collected from continuous glucose monitoring systems (e.g., Dexcom G6 or equivalent), which record interstitial glucose every 5 minutes. TIR will be calculated over the monitoring period using standard CGM metrics, following international consensus guidelines. Justification: TIR has been endorsed as a key metric in diabetes management by the International Consensus on Time in Range. It correlates with reduced risk of microvascular complications and complements traditional measures such as HbA1c.
Time frame: From baseline (hospital discharge) to 12 weeks post-discharge
Time Below Range
Percentage of time that interstitial glucose values are below the target range (\<70 mg/dL), as measured by continuous glucose monitoring (CGM). TBR will be subdivided into: Time in level 1 hypoglycemia: 54-69 mg/dL Time in level 2 hypoglycemia: \<54 mg/dL These thresholds align with the International Consensus on Time in Range. Unit of Measurement: Percentage (%) of time below range Method of Assessment: Data will be extracted from CGM devices (DEXCOM ONE +). The percentage of time spent below each threshold will be calculated using validated software platforms following consensus CGM data analysis protocols.
Time frame: From baseline (hospital discharge) to 12 weeks post-discharge
Time Above Range
Percentage of time that interstitial glucose values are above the target range (\>180 mg/dL), as measured by CGM. TAR will be subdivided into: Time in level 1 hyperglycemia: 181-250 mg/dL Time in level 2 hyperglycemia: \>250 mg/dL Unit of Measurement: Percentage (%) of time above range Method of Assessment: Data will be extracted from CGM device (DEXCOM ONE +). The percentage of time spent above each threshold will be calculated using validated software platforms following consensus CGM data analysis protocols.
Time frame: From baseline (hospital discharge) to 12 weeks post-discharge
Coefficient of Variation
The coefficient of variation (CV) of interstitial glucose values over the monitoring period. CV represents glycemic variability and is calculated as the ratio of the standard deviation to the mean glucose level, expressed as a percentage. Unit of Measurement: Percentage (%) Method of Assessment: Calculated automatically from CGM data using standard formula: CV = (SD / Mean) × 100. The value will be derived from at least 10 days of valid CGM data, in line with consensus guidelines.
Time frame: From baseline (hospital discharge) to 12 weeks post-discharge
Mean Glucose Level
Average interstitial glucose level (mg/dL) measured over the CGM monitoring period. This reflects overall glycemic exposure during the follow-up. Unit of Measurement: Milligrams per deciliter (mg/dL) Method of Assessment: Mean glucose will be calculated from CGM recordings collected over the study period, requiring at least 70% device wear-time for valid analysis.
Time frame: From baseline (hospital discharge) to 12 weeks post-discharge
Glycated Hemoglobin (HbA1c)
Measurement of glycated hemoglobin (HbA1c), which reflects the average blood glucose concentration over the previous 2-3 months. HbA1c is a standard laboratory marker used to assess long-term glycemic control in patients with diabetes. Unit of Measurement: Percentage (%) Method of Assessment: HbA1c will be obtained through standard blood analysis performed during hospitalization and at the 12-week follow-up visit.
Time frame: At 12 weeks post-discharge
Health-related quality of life assessed using the EQ-5D-5L (EuroQol)
Assessment of patient health-related quality of life. It will be assessed using the EQ-5D-5L (EuroQol). Outcomes will include the EQ-5D-5L index value derived from the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and the EQ visual analogue scale (EQ V Unit of measurement EQ-5D-5L index value (unitless score) EQ visual analogue scale (EQ VAS), points (0-100) Method of assessment Self-administered EQ-5D-5L questionnaire, including 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) with 5 levels each, and the EQ VAS. Higher scores indicate better perceived health status.
Time frame: At 12 weeks post-discharge
Re-hospitalization Rate
Evaluation of the rate of unplanned hospital readmissions within 30 days following hospital discharge. A sub-analysis will be conducted to classify readmissions based on whether the primary cause was diabetes-related (e.g., hypoglycemia, hyperglycemia, diabetic complications) or non-diabetes-related. Unit of Measurement: Percentage (%) of participants experiencing hospital readmission. Method of Assessment: Hospital readmission data will be obtained through review of electronic health records and patient interviews. Only unplanned hospitalizations will be included; planned admissions (e.g., scheduled procedures) will be excluded.
Time frame: Within 30 days post-discharge
Number of off-schedule insulin administrations
Evaluation of the number of insulin doses administered outside the recommended time window. This includes basal insulin doses administered more than 60 minutes later than scheduled and bolus insulin doses administered more than 15 minutes after the start of the meal. This outcome reflects deviations from the prescribed insulin timing and may indicate suboptimal treatment adherence or workflow issues. Unit of Measurement: Number of delayed insulin doses per participant Method of Assessment: Data will be obtained from a connected insulin pen device (Insulclock®), which automatically logs the date and time of each insulin administration. Meal times and prescription schedules will be recorded to determine whether each dose was administered on time or delayed.
Time frame: From hospital discharge to 12 weeks post-discharge
Number of participants with abnormal laboratory tests results
Several analytical parameters will be assessed in the participants and reported in the Outcome Measure results data table. Blood and urine samples will be collected and analyzed in certified clinical laboratories using standard methods. The following parameters will be measured: Blood parameters (units): Fasting glucose: mg/dL Uric acid: mg/dL GGT: U/L Total cholesterol: mg/dL HDL cholesterol: mg/dL LDL cholesterol: mg/dL Triglycerides: mg/dL ALT (GPT): U/L AST (GOT): U/L Sodium: mEq/L Potassium: mEq/L Chloride: mEq/L Estimated glomerular filtration rate (eGFR): mL/min/1.73m² Creatinine: mg/dL Albumin: g/dL Glycated hemoglobin (HbA1c): % C-peptide: ng/mL FIB-4 index: unitless Urine parameters: Albumin-to-creatinine ratio (ACR): mg/g creatinine Urine culture: positive / negative (qualitative)
Time frame: During index hospitalization (baseline) and 12 weeks post-discharge
Use of corticosteroids during hospitalization
Description: Assessment of whether the patient received systemic corticosteroids at any point during the index hospitalization. Unit of Measurement: Yes / No Method of Assessment: Information will be obtained from the electronic medical record.
Time frame: During hospitalization (baseline)
Use of corticosteroids at discharge
Assessment of whether the patient was prescribed systemic corticosteroids at the time of hospital discharge. Unit of Measurement: Yes / No Method of Assessment: Information will be obtained from the hospital discharge summary in the electronic medical record.
Time frame: At hospital discharge to 12 weeks post-discharge
Insulin dose intensity at discharge
Assessment of total daily insulin dose prescribed at discharge, categorized as ≥0.5 or \<0.5 units/kg/day. Unit of Measurement: Dichotomous: ≥0.5 units/kg/day vs. \<0.5 units/kg/day Method of Assessment: Total daily insulin dose and patient body weight will be extracted from the medical record to calculate the units per kilogram per day.
Time frame: Baseline
Insulin dose intensity 12 weeks post-discharge
Assessment of total daily insulin dose prescribed at 12 weeks post-discharge, categorized as ≥0.5 or \<0.5 units/kg/day. Unit of Measurement: Dichotomous: ≥0.5 units/kg/day vs. \<0.5 units/kg/day Method of Assessment: Total daily insulin dose and patient body weight will be extracted from the medical record to calculate the units per kilogram per day.
Time frame: 12 weeks post-discharge
Length of hospital stay
Duration of the index hospitalization, expressed in total number of days from admission to discharge. Unit of Measurement: Number of days Method of Assessment: Calculated from hospital admission and discharge dates recorded in the electronic medical record.
Time frame: During hospitalization
Use of oral antidiabetic drugs at discharge
Assessment of whether the patient was prescribed any oral antidiabetic medication at the time of hospital discharge. In addition to the yes/no categorization, the specific type(s) of oral antidiabetic agents prescribed (e.g., metformin, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylureas, etc.) will also be recorded. Unit of Measurement: Yes / No; plus descriptive list of prescribed agents Method of Assessment: Data will be obtained from the discharge medication list recorded in the electronic medical record. The presence or absence of oral antidiabetic therapy will be noted, along with the names of the active substances prescribed.
Time frame: at hospital discharge and at 12 weeks post-discharge
Body Weight
Measurement of body weight taken with a calibrated scale during hospitalization (baseline) and at 12 weeks post-discharge to assess changes in body composition. Unit of Measurement: Kilograms (kg) Method of Assessment: Weight will be measured using a calibrated digital scale at both time points.
Time frame: Baseline (hospitalization) and at 12 weeks post-discharge
Height
Measurement of participant height to calculate body mass index and assess baseline anthropometrics. Unit of Measurement: Meters (m) Method of Assessment: Height will be measured using a stadiometer at enrollment.
Time frame: Baseline (hospitalization)
Body Mass Index (BMI)
Calculation of body mass index (BMI) using weight and height measured at baseline. Unit of Measurement: Kilograms per square meter (kg/m²) Method of Assessment: BMI will be calculated as weight (kg) divided by height squared (m²)
Time frame: Baseline (hospitalization) and at 12 weeks post-discharge
Global cardiovascular risk category
Categorization of participants into global cardiovascular risk groups according to clinical criteria defined in the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Risk levels are determined without the use of SCORE or SCORE2 equations, based on comorbidities, lipid levels, blood pressure, diabetes duration, kidney function, and the presence of established cardiovascular disease or target organ damage. Unit of Measurement: Categorical: Low / Moderate / High / Very high Method of Assessment: Participants will be classified into one of four risk categories: Very high risk: Established cardiovascular disease, chronic kidney disease stage IV (eGFR \<30 mL/min), diabetes with target organ damage or ≥3 major cardiovascular risk factors, or long-standing type 1 diabetes (\>20 years) High risk: Diabetes duration ≥10 years or with additional risk factors, familial hypercholesterolemia without organ damage, chronic kidney disease stage III
Time frame: Baseline (hospitalization)
Medication adherence assessed by the 4-item Morisky-Green test (MMAS-4)
Brief description Medication adherence assessed using the 4-item Morisky-Green test (MMAS-4). Unit of measurement Morisky-Green adherence classification (complier vs non-complier). Method of assessment Self-reported 4-item Morisky-Green questionnaire (yes/no responses). Participants are classified as adherent (complier) when all responses indicate adherence; otherwise, they are classified as non-adherent (non-complier).
Time frame: At 12 weeks post-discharge
Plan to share: No
Ran from Aug 2024 to primary completion in Oct 2026, 26 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 26 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jul 2026 → Oct 2026 and completion Jul 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigacion Sanitaria La Fe